Literature DB >> 30417547

Ecto-5'-nucleotidase (CD73) is a potential target of hepatocellular carcinoma.

Shalaimaiti Shali1, Jiangang Yu1, Xin Zhang1, Xue Wang1, Youping Jin1, Minsheng Su1, Xiaohong Liao1, Jerry Yu2, Xiuling Zhi1, Ping Zhou1.   

Abstract

High expression of ecto-5'-nucleotidase (CD73) has been reported in a number of epithelium origin malignancies. Here, we hypothesize that CD73 promotes hepatocellular carcinoma (HCC) growth and metastasis and that the effect is mediated by epithelial growth factor receptor (EGFR). HCC cells with different malignancies and Tissue microarrays of the tumor and peritumoral liver tissues from 30 independent patients were used to examine CD73 and EGFR expression. Then, MTT and Ki67 detection, together with cell adhesion, invasion, and migration assays were used to evaluate the effects of CD73 on cell growth and metastasis. The expression of EGFR in HCC cells was also tested after suppressing or overexpressing CD73. Lastly, tumor tissues from nude mice, which had been injected subcutaneously with HCC cells, were transplanted subcutaneously into CD73-/- and wild-type (WT) C57 mice. CD73 expression was higher in HCC cells with greater metastatic potentials and tumor tissues compared with low metastatic cells and peritumor tissues. CD73 and EGFR were coexpressed and positively correlated in tumor and peritumor liver tissues in HCC tissue microarrays. Up-regulationof CD73 by plasmid transfection or by pharmacological agents promoted EGFR expression in HCC cells, whereas suppression of CD73 inhibited these effects. The growth of transplanted tumor tissues was dramatically slower in CD73-/- mice than in WT type mice in the in vivo experiments. CD73 promotes HCC growth and metastasis and upregulated the expression of EGFR in HCC. Thus, CD73 and EGFR are potential targets in the treatment of HCC.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  CD73; adenosine; epithelial growth factor receptor (EGFR); hepatocellular carcinoma (HCC); knockout mouse

Mesh:

Substances:

Year:  2018        PMID: 30417547     DOI: 10.1002/jcp.27694

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  10 in total

1.  Cancer-associated fibroblasts enhance the chemoresistance of CD73+ hepatocellular carcinoma cancer cells via HGF-Met-ERK1/2 pathway.

Authors:  Hao Peng; Rong Xue; Zheng Ju; Jiannan Qiu; Jiawei Wang; Wei Yan; Xiaojie Gan; Yizhu Tian; Hongbin Shen; Xiaoming Wang; Xuehao Wang; Xuhao Ni; Yue Yu; Ling Lu
Journal:  Ann Transl Med       Date:  2020-07

Review 2.  Purinergic Signaling in Liver Pathophysiology.

Authors:  Shanu Jain; Kenneth A Jacobson
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-11       Impact factor: 5.555

3.  CD73 promotes cervical cancer growth via EGFR/AKT1 pathway.

Authors:  Chong Liu; Zhao-Wei Gao; Xi Wang; Fang Lin; Hui-Zhong Zhang; Ke Dong
Journal:  Transl Cancer Res       Date:  2022-05       Impact factor: 0.496

Review 4.  Autocrine and paracrine purinergic signaling in the most lethal types of cancer.

Authors:  M Reyna-Jeldes; M Díaz-Muñoz; J A Madariaga; C Coddou; F G Vázquez-Cuevas
Journal:  Purinergic Signal       Date:  2021-05-12       Impact factor: 3.765

5.  CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis.

Authors:  Xiao-Lu Ma; Min-Na Shen; Bo Hu; Bei-Li Wang; Wen-Jing Yang; Li-Hua Lv; Hao Wang; Yan Zhou; An-Li Jin; Yun-Fan Sun; Chuan-Yan Zhang; Shuang-Jian Qiu; Bai-Shen Pan; Jian Zhou; Jia Fan; Xin-Rong Yang; Wei Guo
Journal:  J Hematol Oncol       Date:  2019-04-11       Impact factor: 17.388

6.  Tumor-Selective Altered Glycosylation and Functional Attenuation of CD73 in Human Hepatocellular Carcinoma.

Authors:  Karel P Alcedo; Andres Guerrero; Venkatesha Basrur; Dong Fu; Monea L Richardson; Joshua S McLane; Chih-Chiang Tsou; Alexey I Nesvizhskii; Theodore H Welling; Carlito B Lebrilla; Carol A Otey; Hong Jin Kim; M Bishr Omary; Natasha T Snider
Journal:  Hepatol Commun       Date:  2019-08-09

Review 7.  CD73, Tumor Plasticity and Immune Evasion in Solid Cancers.

Authors:  Haitang Yang; Feng Yao; Paul F Davis; Swee T Tan; Sean R R Hall
Journal:  Cancers (Basel)       Date:  2021-01-07       Impact factor: 6.639

Review 8.  Advances in immunotherapy for hepatocellular carcinoma.

Authors:  Bruno Sangro; Pablo Sarobe; Sandra Hervás-Stubbs; Ignacio Melero
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-04-13       Impact factor: 73.082

Review 9.  Current Adenosinergic Therapies: What Do Cancer Cells Stand to Gain and Lose?

Authors:  Jana Kotulová; Marián Hajdúch; Petr Džubák
Journal:  Int J Mol Sci       Date:  2021-11-22       Impact factor: 5.923

10.  Inhibition of ABCC6 Transporter Modifies Cytoskeleton and Reduces Motility of HepG2 Cells via Purinergic Pathway.

Authors:  Angela Ostuni; Monica Carmosino; Rocchina Miglionico; Vittorio Abruzzese; Fabio Martinelli; Daniela Russo; Ilaria Laurenzana; Agata Petillo; Faustino Bisaccia
Journal:  Cells       Date:  2020-06-05       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.